Fortunak J - Search Results

1

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Hill A, et al. Among authors: fortunak j. Clin Infect Dis. 2014 Apr;58(7):928-36. doi: 10.1093/cid/ciu012. Epub 2014 Jan 6. Clin Infect Dis. 2014. PMID: 24399087 Free PMC article.

2

Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.

Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C; participants of Conference on Antiretroviral Drug Optimization. Crawford KW, et al. Lancet Infect Dis. 2012 Jul;12(7):550-60. doi: 10.1016/S1473-3099(12)70134-2. Lancet Infect Dis. 2012. PMID: 22742638

3

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.

van de Ven N, Fortunak J, Simmons B, Ford N, Cooke GS, Khoo S, Hill A. van de Ven N, et al. Among authors: fortunak j. Hepatology. 2015 Apr;61(4):1174-82. doi: 10.1002/hep.27641. Epub 2015 Feb 9. Hepatology. 2015. PMID: 25482139 Free PMC article.

4

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.

Hill A, Gotham D, Fortunak J, Meldrum J, Erbacher I, Martin M, Shoman H, Levi J, Powderly WG, Bower M. Hill A, et al. Among authors: fortunak j. BMJ Open. 2016 Jan 27;6(1):e009586. doi: 10.1136/bmjopen-2015-009586. BMJ Open. 2016. PMID: 26817636 Free PMC article.

5

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries.

Hill A, Gotham D, Cooke G, Bhagani S, Andrieux-Meyer I, Cohn J, Fortunak J. Hill A, et al. Among authors: fortunak j. J Virus Erad. 2015 Apr 1;1(2):103-10. doi: 10.1016/S2055-6640(20)30484-2. J Virus Erad. 2015. PMID: 27482399 Free PMC article.

6

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C.

Hill A, Simmons B, Gotham D, Fortunak J. Hill A, et al. Among authors: fortunak j. J Virus Erad. 2016 Jan 1;2(1):28-31. doi: 10.1016/S2055-6640(20)30691-9. J Virus Erad. 2016. PMID: 27482432 Free PMC article.

7

Estimated generic prices for novel treatments for drug-resistant tuberculosis.

Gotham D, Fortunak J, Pozniak A, Khoo S, Cooke G, Nytko FE 3rd, Hill A. Gotham D, et al. Among authors: fortunak j. J Antimicrob Chemother. 2017 Apr 1;72(4):1243-1252. doi: 10.1093/jac/dkw522. J Antimicrob Chemother. 2017. PMID: 28073970 Free article.

8

Minimum costs to manufacture new treatments for COVID-19.

Hill A, Wang J, Levi J, Heath K, Fortunak J. Hill A, et al. Among authors: fortunak j. J Virus Erad. 2020 Apr 30;6(2):61-69. doi: 10.1016/S2055-6640(20)30018-2. J Virus Erad. 2020. PMID: 32405423 Free PMC article.

9

Current prices versus minimum costs of production for CFTR modulators.

Guo J, Wang J, Zhang J, Fortunak J, Hill A. Guo J, et al. Among authors: fortunak j. J Cyst Fibros. 2022 Sep;21(5):866-872. doi: 10.1016/j.jcf.2022.04.007. Epub 2022 Apr 16. J Cyst Fibros. 2022. PMID: 35440408 Free article.

10

Lenacapavir to prevent HIV infection: current prices versus estimated costs of production.

Hill A, Levi J, Fairhead C, Pilkington V, Wang J, Johnson M, Layne J, Roberts D, Fortunak J. Hill A, et al. Among authors: fortunak j. J Antimicrob Chemother. 2024 Nov 4;79(11):2906-2915. doi: 10.1093/jac/dkae305. J Antimicrob Chemother. 2024. PMID: 39225016

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters